MARIETTA, Ga., Jan. 12, 2018 /PRNewswire/ -- MiMedx Group, Inc.
(NASDAQ: MDXG), the leading biopharmaceutical company developing
and marketing regenerative and therapeutic biologics utilizing
human placental tissue allografts with patent-protected processes
for multiple sectors of healthcare, announced that it will host a
webcast on Thursday, January 18, 2018
beginning at 10:30 a.m. eastern
time.
The Company reported that "Pete" Petit, Chairman and CEO;
Bill Taylor, President and COO;
Chris Cashman, EVP and Chief
Commercialization Officer; and Debbie
Dean, Executive Vice President, will be presenting during
the January 18th
call.
The Company expects the formal presentation to last
approximately 45 minutes, after which the call will be open for
questions and answers. The subject matter to be covered will
include:
- Status of Plantar Fasciitis Phase 2B IND study, Plantar Fasciitis Phase 3 IND
study, Achilles Tendonitis Phase 3 IND study, and Osteoarthritis
IND Phase 2B study;
- Plans for submitting a Biologic License Application (BLA) to
the FDA for tendonitis when the Plantar Fasciitis and Achilles
Tendonitis Phase 3 trials are completed;
- Impact of Recent Successful Settlement of Patent Infringement
Lawsuit; and
- Status of Incremental Health Plan Coverage as result of VLU
Clinical Study
A listen-only simulcast of this MiMedx shareholder call will be
available on the Company's website at www.mimedx.com beginning
at 10:30 a.m. eastern time,
January 18, 2018. A 30-day on-line
replay will be available on the Company's website approximately one
hour following the conclusion of the live broadcast.
About MiMedx
MiMedx® is the leading biopharmaceutical
company developing and marketing regenerative and therapeutic
biologics utilizing human placental tissue allografts with
patent-protected processes for multiple sectors of healthcare.
"Innovations in Regenerative Medicine" is the
framework behind our mission to give physicians products and
tissues to help the body heal itself. We process the human
placental tissue utilizing our proprietary PURION® Process among
other processes, to produce safe and effective
allografts. MiMedx proprietary processing methodology
employs aseptic processing techniques in addition to terminal
sterilization. MiMedx is the leading supplier of placental
tissue, having supplied over 1 million allografts to date for
application in the Wound Care, Burn, Surgical, Orthopedic, Spine,
Sports Medicine, Ophthalmic and Dental sectors of healthcare. For
additional information, please visit www.mimedx.com.
View original
content:http://www.prnewswire.com/news-releases/mimedx-to-host-shareholder-call-on-january-18-2018-to-update-progress-on-multiple-clinical-studies-and-status-of-patent-portfolio-300582262.html
SOURCE MiMedx Group, Inc.